Core CMI
Since 1993 pharmaceutical manufacturers have been providing Consumer Medicine Information (CMI) to help consumers better understand the medicines they take.
CMIs are typically made available to consumers by their doctors and pharmacists as part of their consultation and dispending services.
Most CMIs are available as an insert in the medicine package. Others are available on an electronic database, accessible by pharmacists, or as a leaflet given to the consumer by the pharmacist.
Although the CMI is prepared by the manufacturer, it has to be factual, contain no advertising material, and must comply with the requirements set down in the Commonwealth Therapeutic Goods Regulations.
A CMI includes:
- The name of the medicine;
- The active ingredients, as well as the inactive ingredients (excipients);
- The dosage form of the medicine (eg tablet, injection or suppository);
- What the medicine is used to treat and how it works;
- Any warnings and precautions, such as when the medicine should not be taken;
- Any interaction the medicine might have with food or other medicines;
- How to use the medicine properly;
- Side effects, if any;
- What to do in the case of an overdose;
- How to store the medicine properly;
- The manufacturers/sponsors name and address; and
- The date the CMI was last updated.
Including all of this information can make a CMI quite long. But all of it is important information. However, in a well-written CMI, a consumer should be able to follow the headings and subheading to easily find out what they need easily.
To ensure that CMIs are written in a manner easily understood by the consumer a Quality Assurance Reference Group was established.
The Quality Assurance Reference Group includes representatives from consumers, doctors, nurses, pharmacists, manufacturers, CMI writers and an expert in communications.
To assist manufacturers develop their CMIs, the Quality Assurance Reference Group has developed a set of templates for the common medicine groups. These templates called ‘Core CMIs’ can be found in the Consumer Medicines Information section of this website, under Core CMIs.
In addition, companies can reference the Writing About Medicines for People Guidelines that describe how to write CMIs in a way that will be most useful to, and easily read by consumers.
The Quality Assurance Group encourages contact from anyone who has a concern about a particular CMI, for example if they think it is unclear or confusing, or something important has been left out. The Quality Assurance Reference group can be contacted through its Chairman, Ms Deborah Monk, on 02 6282 6888 pr by writing c/- Medicines Australia, 16 Napier Close, Deakin ACT, 2600.
For more information on CMI’s go to http://www.health.gov.au/internet/main/publishing.nsf/Content/nmp-consumers-cmi.htm. This link goes to the government’s health site where it has some valuable information.
To assist manufacturers develop their CMIs, the Quality Assurance Reference Group has developed a set of templates for the common medicine groups. These templates called ‘Core CMIs’ can be found below:
Please contact Elizabeth de Somer on (02) 6122 8525 for more information.
- Core CMI for General Core CMI
214k - Vocabulary for CMI – an Explanatory Note
273k - Core CMI for ACE Inhibitors
83k - Core CMI for Adult Injectable Vaccines
62k - Core CMI for Anti-Anginal Medicines
34k - Core CMI for Anticonvulsant Medicines
101k - Core CMI for Antidepressant Medicines
41k - Core CMI for Antihistamine Medicines
87k - Core CMI for Antipsychotic Medicines
103k - Core CMI for Benzodiazapines
34k - Core CMI for Cephalosporin Antibiotics
34k - Core CMI for Cholesterol lowering Agents (Hypolipidaemics)
36k - Core CMI for Codeine
55k - Core CMI for Dextromethorphan
53k - Core CMI for Diuretics
46k - Core CMI for Drugs used to treat Glaucoma
53k - Core CMI for Guaiphenesin
51k - Core CMI for Hormonal Antineoplastic Agents
94k - Core CMI for Human Insulin Injectables
234k - Core CMI for Drugs used to treat Hyperacidity, Reflex and Ulcers
30k - Core CMI for Inhalation Asthma Medicines
40k - Core CMI for Injections for Adult and Paediatric use
71k - Core CMI for Macrolide Antibiotics
37k - Core CMI for Nasal Corticosteroids
218k - Core CMI for Nitroimidazole Antibiotics
34k - Core CMI for NSAIDs
43k - Core CMI for Non-Hormonal Antineoplastic Agents
117k - Core CMI for Oral Asthma Medicines
38k - Core CMI for Oral Hypoglycaemic Medicines
51k - Core CMI for Oral Vaccines for Adult and Paediatric use
32k - Core CMI for Paediatric Injectable Vaccines
65k - Core CMI for Paracetamol
52k - Core CMI for Penicillin Antibiotics
35k - Core CMI for Pholcodine
52k - Core CMI for Pseudoephedrine
52k - Core CMI for Pseudoephedrine – General Guidance
21k - Core CMI for Quinolone Antibiotics
36k - Core CMI for Sedating Antihistamines
55k - Core CMI for Tetracycline Antibiotics
36k - Core CMI for Topical Corticosteroids
58k
Page updated: August 2011
